Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous,low grade serous and low grade endometrioid ovarian cancer - Centre Georges Francois Leclerc Accéder directement au contenu
Article Dans Une Revue Journal of Gynecology Obstetrics and Human Reproduction Année : 2021

Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous,low grade serous and low grade endometrioid ovarian cancer

Cyril Touboul
  • Fonction : Auteur
Yohann Dabi
  • Fonction : Auteur
Pierre-Adrien Bolze
Alexandre Bricou
  • Fonction : Auteur
  • PersonId : 1085065
Emile Darai
  • Fonction : Auteur

Résumé

BACKGROUND: The aim of this study was to evaluate the impact of lymphovascular space invasion (LVSI) on overall survival (OS) and recurrence-free survival (RFS) in patients managed for stage I-IIa clear cell carcinoma, mucinous, low-grade serous and low-grade endometrioid ovarian cancer MATERIAL AND METHODS: Retrospective multicentre study of the research group FRANCOGYN between January 2001 and December 2018. All patients managed for stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer and for whom the presence of histological slides for the review of LVSI was available, were included. Patient’s characteristics with LVSI (LVSI group) were compared to those without LVSI (No LVSI group). A cox analysis for OS and RFS analysis were performed in all population. RESULTS: Over the study period, 133 patients were included in the thirteen institutions. Among them, 12 patients had LVSI (9%). LVSI was an independent predictive factor for poorer Overall and recurrence free survivals. LVSI affected OS (p<0.001) and RFS (p=0.0007), CONCLUSION: The presence of LVSI in stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer has an impact on OS and RFS and should put them at high risk and consider the option of adjuvant chemotherapy.
Fichier principal
Vignette du fichier
Delvallée et al. - 2021 - Lymphovascular invasion as a criterion for adjuvan.pdf (401.78 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03283101 , version 1 (16-07-2021)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Julie Delvallée, Mathilde Cancel, Gilles Body, Sofiane Bendifallah, Cyril Touboul, et al.. Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous,low grade serous and low grade endometrioid ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50 (10), pp.102193. ⟨10.1016/j.jogoh.2021.102193⟩. ⟨hal-03283101⟩
254 Consultations
104 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More